The Trump Administration Secures Landmark Deals to Slash Obesity Drug Prices
Agreements with Eli Lilly and Novo Nordisk aim to expand access to GLP-1 treatments through Medicare and new TrumpRx platform. Washington, D.C. – November 7, 2025 — The Trump administration has announced sweeping agreements with pharmaceutical giants Eli Lilly and Novo Nordisk to dramatically reduce the cost of GLP-1 obesity and diabetes drugs, including Wegovy, […]
Continue Reading